Comparative Pharmacology
Head-to-head clinical analysis: STADOL versus STADOL PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STADOL versus STADOL PRESERVATIVE FREE.
STADOL vs STADOL PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at mu-opioid receptors and agonist at kappa-opioid receptors in the CNS, altering pain perception and emotional response to pain.
Butorphanol is a synthetic agonist-antagonist opioid analgesic that exerts its effects primarily through binding to kappa-opioid receptors and, to a lesser extent, mu-opioid receptors, producing analgesia and sedation. It also has partial antagonist activity at mu receptors.
Butorphanol tartrate 1-2 mg IV or IM every 3-4 hours as needed for pain; alternatively, 0.5-1 mg IV every 3-4 hours. For nasal spray: 1 mg (one spray) in one nostril, may repeat in 60-90 minutes if needed; then 1 mg every 3-4 hours as needed.
0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed for pain. Alternatively, 1–2 mg as a single dose, may repeat in 30–60 minutes if needed.
None Documented
None Documented
Terminal elimination half-life: 2.5-4 hours; clinically, prolonged in hepatic impairment (up to 10-12 hours) and elderly
Terminal elimination half-life is 2.5–3.3 hours in adults; prolonged to 4–6 hours in elderly or hepatic impairment.
Renal: 85-90% as unchanged drug and metabolites (primarily as glucuronide conjugates); Fecal: <10%; Biliary: minimal
Primarily hepatic metabolism (glucuronidation) to inactive metabolites; renal excretion accounts for <5% unchanged drug. Approximately 70% of dose excreted in urine as metabolites, 20% in feces.
Category C
Category C
Opioid Analgesic
Opioid Analgesic